Multiple sequential insults cause post-pump syndrome

Annals of Thoracic Surgery

Volumn 67, Issue 4, 1999, Pages 978-985

  Picone, Anthony L ^a   Lutz, Charles J ^a   Finck, Christine ^a   Carney, David ^a   Gatto, Louis A ^a   Paskanik, Andrew ^a   Searles, Bruce ^a   Snyder, Kathy ^a   Nieman, Gary ^a,b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; HEPARIN; PROTAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; HEMODYNAMICS; LEUKOCYTE ACTIVATION; MONOCYTE; MORPHOMETRICS; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PUMP; RESPIRATORY DISTRESS; SWINE;

ANIMALS; CARDIOPULMONARY BYPASS; ENDOTOXINS; HYPOTHERMIA, INDUCED; NEUTROPHILS; RESPIRATORY DISTRESS SYNDROME, ADULT; SWINE;

EID: 0032915531     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(99)00093-4     Document Type: Article

References (32)

1. Messent M., Sullivan K., Keogh B.F., et al. Adult respiratory distress syndrome following cardiopulmonary bypass incidence and prediction . Anaesthesia. 47:1992;267-268.
2. Starr N.J. Foreward. Casthely P.A., Bregman D. Cardiopulmonary bypass: physiology, related complications and pharmacology. 1991;iii Furtura, New York.
3. Finn A., Morgan B.P., Rebuck N., et al. Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11B/CD18 and L-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary bypass. J Thorac Cardiovasc Surg. 111:(2):1996;451-459.
4. Steinberg B.M., Grossi E.A., Schwartz D.S., et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg. 60:1995;525-529.
5. Lundblad R., Moen O., Fosse E. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 63:1997;1361-1367.
6. Fosse E., Moen O., Johnson E., et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 58:1994;472-477.
7. Redmond J.M., Gillinov A.M., Stuart S., et al. Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg. 56:1993;474-479.
8. Partrick D.A., Moore F.A., Moore E.E., Barnett C.C., Silliman C.C. Neutrophil priming and activation in the pathogenesis of post injury multiple organ failure. New Horiz. 4:1996;194-210.
9. Anderson B.O., Brown J.M., Bensard D.D., et al. Reversible lung neutrophil accumulation can cause lung injury by elastase-mediated mechanisms. Surgery. 108:1990;262-268.
10. Worthen G.S., Haslett C., Rees A.J., Gumbay R.S., Henson J.E., Henson P.M. Neutrophil-mediated pulmonary vascular injury synergistic effect of trace amounts of lipopolysaccharide and neutrophil stimuli on vascular permeability and neutrophil sequestration in the lung . Am Rev Resp Dis. 136:1987;19-28.
11. Okusawa S., Gerlfand J., Ikejima I., Connolly R., Dinarello C. Interleukin-1 produces a shock-like state in rabbits synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition . J Clin Invest. 81:1988;1162-1172.
12. 2 regulates critical inflammatory mediators of multiple organ failure. J Surg Res. 56:1994;199-205.
13. Kim F.J., Moore E.E., Moore F.A., Biffl W.L., Fontes B., Banerjee A. Reperfused gut elaborates PAF that chemoattracts and primes neutrophils. J Surg Res. 58:1996;636-640.
14. Moore E.E., Moore F.A., Franciose R.J., Kim F.J., Biffl W.L., Banerjee A. The postischemic gut serves as a priming bed for circulating neutrophils that provoke multiple organ failure. J Trauma. 37:1994;881-887.
15. Koike K., Moore F.A., Moore E.E., Poggetti R.S., Tuder R.M., Banerjee A. Endotoxin after gut ischemia/reperfusion causes irreversible lung injury. J Surg Res. 52:1992;656-662.
16. 2 mediates neutrophil priming and lung injury after mesenteric ischemia-reperfusion. Am J Physiol (Gastrointest Liver Physiol 31). 268:1995;G397-G403.
17. Cummings J.J., Suter S., Girardin E., Roux L.P., Grau G.E., Dayer J.M. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs. Am Rev Respir Dis. 145:1992;999-1004.
18. Lutz C.J., Picone A., Gatto L.A., Paskanik A.P., Landas S., Nieman G.F. Exogenous surfactant and positive end-expiratory pressure in the treatment of endotoxin-induced lung injury. Crit Care Med. 26:1998;1379-1389.
19. Gundersen H.J. Estimators of the number of objects per area unbiased by edge effects. Microsc Acta. 81:(2):1978;107-117.
20. Tennenberg S.D., Clardy C.W., Bailey W.W., Solomkin J.S. Complement activation and lung permeability during cardiopulmonary bypass. Ann Thorac Surg. 50:1990;597-601.
21. Lundblad R., Moen O., Fosse E. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 63:1997;1361-1367.
22. Goodman R.B., Strieter R.M., Martin D.P., et al. Inflammatory cytokine in patients with persistence of acute respiratory distress syndrome. Am J Resp Crit Care Med. 154:1996;602-611.
23. Friedman M., Wang S.Y., Sellke F.W., Franklin A., Weintraub R.M., Johnson R.G. Pulmonary injury after total or partial cardiopulmonary bypass with thromboxane synthesis inhibition. Ann Thorac Surg. 598:1995;598-603.
24. Zehr K.J., Poston R.S., Lee P.C., et al. Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass. Ann Thorac Surg. 59:1995;328-335.
25. Hirthler M., Simoni J., Dickson M. Elevated levels of endotoxin, oxygen-derived free radicals, and cytokines during extracorporeal membrane oxygenation. J Ped Surg. 27:1992;119-120.
26. Westaby S. Organ dysfunction after cardiopulmonary by-pass. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med. 13:1987;89-95.
27. Jansen N.J.G., van Oeveren W., Broek L., et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 102:1991;515-525.
28. Gillinov A.M., DeValeria P.A., Winkelstein J.A., et al. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg. 55:1993;619-624.
29. Gu Y.J., van Oeveren W., Boonstra P.W., DeHaan J., Wildevuur C.R.H. Leukocyte activation with increased expression of CR3 receptors during cardiopulmonary bypass. Ann Thorac Surg. 53:1992;839-843.
30. Sinclair D.G., Haslam P.L., Quinlan G.J., Pepper J.R., Evans T.W. The effect of cardiopulmonary bypass on intestinal and pulmonary endothelial permeability. Chest. 108:1995;718-724.
31. Jansen N.J.G., van Oeveren W., Gu Y.J., van Vliet M.H., Eijsman L., Wildevuur C.R.H. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg. 54:1992;744-748.
32. Rocke D.A., Gaffin S.L., Wells M.T., Koen Y., Brock-Utine J.G. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 93:1987;832-837.